Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H28N4O3.ClH |
Molecular Weight | 505.008 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C4=C(C(=O)NC4=O)C5=CN(CCO1)C6=CC=CC=C56
InChI
InChIKey=NYQIEYDJYFVLPO-FERBBOLQSA-N
InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
DescriptionSources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500068826.pdfCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23404115 | https://www.ncbi.nlm.nih.gov/pubmed/19825373 | https://www.ncbi.nlm.nih.gov/pubmed/15380221
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500068826.pdf
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23404115 | https://www.ncbi.nlm.nih.gov/pubmed/19825373 | https://www.ncbi.nlm.nih.gov/pubmed/15380221
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and ameliorates many of the effects of PKC β on pathologic processes in the retina. Ruboxistaurin prevents the slowing of retinal blood flow that is observed by fluorescein video angiography in the eyes of diabetic rats. It is also reported to cause regression of retinal neovascularization produced by laser-induced major branch vein occlusions in a porcine model. Ruboxistaurin positively affected the diabetes-induced retinal blood flow abnormalities in a Phase Ib study in diabetic patients. Ruboxistaurin is in phase III clinical trials for the treatment of diabetic nephropathy and diabetic macular edema. Eli Lilly had submitted Ruboxistaurin for approval in the US and the EU; however, the company subsequently discontinued development as it was unable to demonstrate sufficient efficacy
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3045 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15380221 |
5.9 nM [IC50] | ||
Target ID: CHEMBL299 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954055 |
360.0 nM [IC50] | ||
Target ID: CHEMBL2938 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954055 |
300.0 nM [IC50] | ||
Target ID: CHEMBL3616 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12749884 |
52.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23404115
32 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19825373
HUVECs co-cultured with fibroblasts were cultivated in the presence or absence of various concentrations of ruboxistaurin (0.1 and 1 mkM) plus VEGF (10 ng/ml) at days 1, 4, 7 and 9. The ruboxistaurin was dissolved in dimethyl sulfoxide (DMSO, final concentration of DMSO was 0.1%). DMSO (0.1%) was added to the non-drug control (control group). At day 11, cells were fixed in 70% ethanol. The cells were incubated with diluted primary antibody (mouse anti-human CD31, 1 : 4000) for 1 h at 37 C, and with the secondary antibody (goat anti-mouse IgG alkaline phosphataseconjugated antibody, 1 : 500) for 1 h at 37 C. Visualization was achieved using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
169939-93-9
Created by
admin on Sat Dec 16 07:58:32 GMT 2023 , Edited by admin on Sat Dec 16 07:58:32 GMT 2023
|
PRIMARY | |||
|
9870785
Created by
admin on Sat Dec 16 07:58:32 GMT 2023 , Edited by admin on Sat Dec 16 07:58:32 GMT 2023
|
PRIMARY | |||
|
6496V4OCZN
Created by
admin on Sat Dec 16 07:58:32 GMT 2023 , Edited by admin on Sat Dec 16 07:58:32 GMT 2023
|
PRIMARY | |||
|
DBSALT002089
Created by
admin on Sat Dec 16 07:58:32 GMT 2023 , Edited by admin on Sat Dec 16 07:58:32 GMT 2023
|
PRIMARY | |||
|
m9693
Created by
admin on Sat Dec 16 07:58:32 GMT 2023 , Edited by admin on Sat Dec 16 07:58:32 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD